Emraclidine - Cerevel Therapeutics
Alternative Names: CVL-231; PF-06852231Latest Information Update: 28 Aug 2024
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics; Pfizer
- Class Antidementias; Antipsychotics; Azetidines; Fluorobenzenes; Ketones; Pyridines; Pyrroles; Small molecules
- Mechanism of Action Muscarinic M4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Schizophrenia
- Phase I Alzheimer's disease
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in Belgium (PO)
- 01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie
- 20 Jun 2024 Cerevel Therapeutics completes phase-I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT06366243)